Bunkerhill Health has closed a $25 million Series B led by Khosla Ventures, with continued participation from Sequoia Capital, Felicis, Optum Ventures and Y Combinator, bringing the company's total funding to $55 million. The round will scale Carebricks, Bunkerhill's platform for letting hospitals and health systems build their own clinical and administrative AI agents rather than rely on off-the-shelf point tools.

An agent-building platform for health systems

Carebricks is pitched less as a single product than as infrastructure: it lets health systems turn their own ideas for automation into working AI agents that span clinical, operational and administrative domains — reviewing cardiology imaging for early signs of heart disease, flagging patients who need follow-up care, navigating prior authorizations, and automating registry management. The platform is already deployed at Cleveland Clinic, the University of Texas Medical Branch (UTMB) and Intermountain Health, among other systems.

Bunkerhill says the impact is already measurable at UTMB, where an FDA-cleared coronary-calcium agent has flagged cases serious enough to trigger emergency interventions, including at least one emergency triple bypass. The company also cites operational gains at deployed sites, including nephrology specialist wait times cut by more than half and urgent incidental lung nodules addressed roughly 80% faster.

"Great ideas are everywhere, we just don't translate them into reality," Bunkerhill co-founder and CEO Nishith Khandwala said of the platform's origin, framing the company's bet as closing the gap between a hospital's automation ideas and a shippable, compliant agent. Khosla Ventures' Vinod Khosla echoed that framing, saying "the bottleneck in healthcare AI was never the technology, it was getting a health system to actually run it."

Why it matters

Healthcare has been one of the more cautious sectors for agentic AI, given the regulatory, liability and integration hurdles around clinical workflows. Bunkerhill's raise — and its list of large academic and nonprofit health-system customers — is a signal that hospitals are moving past pilot-stage chatbots toward agents that touch real clinical decisions and administrative workflows at scale, with FDA clearance and measurable outcomes as the bar for adoption rather than novelty. It also reflects a broader shift in enterprise AI-agent funding toward vertical, workflow-specific platforms over general-purpose agent tooling.